DexCom stock
DXCMNASDAQDexCom, Inc., HealthcareISIN US2521311074
78Score 78 out of 100, Strong
Price and trend
65 / 100
Price history
+38% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.1% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 13% below its 52-week high. Largest decline in 20 years: 87% (October 2007 to November 2008).
Chart figures for advanced users
- SMA 50$84.59
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$74.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$57.56
- The lowest closing price of the last twelve months.
- Resistance$92.34
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- DexCom, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $29.97B, is number 9 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.66B (up 15.6% year on year) and earnings of $836.3M (up 45.1%).
- For fiscal 2026, analysts expect on average revenue of $5.23B (up 12.2%) and adjusted earnings per share of $2.70 (up 29.3%).
Show more
- MEQIRI Score 78 out of 100 (Strong): rank 33 of 714 in Healthcare, median 53.
- The P/E is 30.9 (Medical (Devices) median 29, own median of recent years 78.4).
- Our model puts fair value at $89.96, with the price 11% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 33% in fiscal 2025, Medical (Devices) median 5.4%.Profitability 91
- High marginNet margin 19.4% over the last 12 months, Medical (Devices) median 3.2%.Profitability 91
- More cash than debtCash $1.82B, financial debt $1.39B.Stability 77
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are profitability and growth.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $69.20 and expensive above $128.52 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $104.50 (cash-flow model) and $75.42 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $80.54, at 7.8% it would be $104.16.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13% on the twelve months before. Revenue has grown strongly since 2006, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 60%, operating 20%, net 18%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 91 days
- Last reported
- 29 Oct 2026EPS reported $0.73 (expected $0.68)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.70+1.3%
- Revenue
- $5.23B0.0%
- Earnings per share
- $3.14+0.6%
- Revenue
- $5.77B−0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +11.1%Guidance raised: revenue $5.18 billion to $5.25 billion (up 11% to 13%), non-GAAP operating margin 23.5% to 24%, adjusted EBITDA margin 31.5% to 32%.
“We are also increasing our non GAAP operating profit margin guidance to a range of 23.5% to 24% and adjusted EBITDA margin guidance to a range of 31.5% to 32%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $12.18M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stern SadieSale
27 Oct 2026, EVP Chief People & Culture Officer
- Shares
- 2,565
- Price
- $78.62
- Value
- $201,660
- Brown Michael JonSale
15 Oct 2026, EVP Chief Legal Compliance Officer
- Shares
- 1,700
- Price
- $85.48
- Value
- $145,316
- Stern SadieSale
28 Sept 2026, EVP Chief People & Culture Officer
- Shares
- 2,565
- Price
- $86.15
- Value
- $220,975
Show 19 more
- Augustinos NicholasSale
15 Sept 2026, Board
- Shares
- 6,539
- Price
- $84.04
- Value
- $549,538
- Brown Michael JonSale
15 Sept 2026, EVP Chief Legal Compliance Officer
- Shares
- 1,700
- Price
- $84.04
- Value
- $142,868
- Augustinos NicholasSale
14 Sept 2026, Board
- Shares
- 1,550
- Price
- $84.02
- Value
- $130,231
- Sylvain Jereme MSale
10 Sept 2026, EVP, Chief Financal Officer
- Shares
- 3,638
- Price
- $83.27
- Value
- $302,936
- Stern SadieSale
27 Aug 2026, EVP Chief People & Culture Officer
- Shares
- 2,565
- Price
- $88.37
- Value
- $226,669
- Sayer Kevin RSale
20 Aug 2026, Executive Chair
- Shares
- 26,756
- Price
- $90.01
- Value
- $2.41M
- Brown Michael JonSale
14 Aug 2026, EVP Chief Legal Compliance Officer
- Shares
- 1,700
- Price
- $91.93
- Value
- $156,281
- Heller Bridgette PSale
12 Aug 2026, Board
- Shares
- 1,012
- Price
- $88.29
- Value
- $89,349
- Foletta Mark GSale
3 Aug 2026, Board
- Shares
- 2,000
- Price
- $85.32
- Value
- $170,640
- Foletta Mark GSale
31 Jul 2026, Board
- Shares
- 2,000
- Price
- $80.00
- Value
- $160,000
- Sayer Kevin RSale
20 Jul 2026, Executive Chair
- Shares
- 26,756
- Price
- $76.32
- Value
- $2.04M
- Brown Michael JonSale
15 Jul 2026, EVP Chief Legal Compliance Officer
- Shares
- 1,700
- Price
- $74.42
- Value
- $126,514
- Sayer Kevin RSale
6 Jul 2026, Executive Chair
- Shares
- 26,756
- Price
- $72.00
- Value
- $1.93M
- Brown Michael JonSale
15 Jun 2026, EVP Chief Legal Compliance Officer
- Shares
- 1,700
- Price
- $75.55
- Value
- $128,435
- Foletta Mark GSale
15 Jun 2026, Board
- Shares
- 4,000
- Price
- $74.13
- Value
- $296,540
- Coleman JonSale
4 Jun 2026, EVP, Chief Commercial Officer
- Shares
- 4,911
- Price
- $74.13
- Value
- $364,052
- Coleman JonSale
3 Jun 2026, EVP, Chief Commercial Officer
- Shares
- 4,912
- Price
- $73.00
- Value
- $358,576
- Sayer Kevin RSale
21 May 2026, Executive Chair
- Shares
- 26,759
- Price
- $72.00
- Value
- $1.93M
- Brown Michael JonSale
15 May 2026, EVP, Chief Legal Officer
- Shares
- 1,700
- Price
- $59.91
- Value
- $101,847
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at DexCom
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Edwards LifesciencesEW $60.84B76
- Siemens HealthineersSHL.DE $54.2B65
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- Koninklijke PhilipsPHIA.AS $29.51B56
- Terumo4543.T $23.31B76
- Zimmer Biomet HoldingsZBH $20.34B68
- Sonova HoldingSOON.SW $20.24B74
ETFs that hold DexCom
Held by 106 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 4.37% | 0.68% | €5.31M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.27% | 0.40% | €1.49B |
| Amundi Global Gender Equality UCITS ETF AccVOOM | 0.57% | 0.20% | €55.72M |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.50% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.49% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.48% | 0.15% | €592.11M |
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.43% | 0.75% | €140.24M |
| Deka MSCI USA MC UCITS ETFEL41 | 0.43% | 0.30% | €51.58M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 10 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.